Search results for " Humans"

showing 10 items of 2466 documents

Light on the molecular and cellular mechanisms of bicuspid aortic valve to unveil phenotypic heterogeneity

2019

Research on bicuspid aortic valve disease (BAV) and related complications has grown in an exponential manner in the last decades. However, the current knowledge of the mechanisms underlying the development of this disease is still limited, since all clinical and surgical studies on BAV mainly focused their objects on its major vascular complications, such as ascending aortic aneurysms and dissection. It is now clear that a better understanding of the pivotal molecular and cellular pathophysiological aspects of bicuspid valve aortopathy, including natural history, phenotypic expression, histology, cellular mechanisms and pathways, is critical for improving its clinical management. This chang…

molecular and cellular mechanismbicuspid aortic valvethoracicphenotypeprecision medicineaortic aneurysm thoracic; aortic valve; biomarkers; heart valve diseases; humans; precision medicine; genetic heterogeneity; phenotypeBiologyBioinformaticsheart valve diseasesgenetic heterogeneityAortic aneurysmBicuspid aortic valveBicuspid Aortic Valve DiseasemedicineSettore MED/05 - Patologia ClinicahumansMolecular BiologyAortic Aneurysm ThoracicGenetic heterogeneitybiomarkersmedicine.diseasePrecision medicineaortic valvePhenotypeCardiology and Cardiovascular Medicineaortic aneurysmJournal of Molecular and Cellular Cardiology
researchProduct

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

2011

International audience; So far, no common environmental and/or phenotypic factor has been associated with melanoma and renal cell carcinoma (RCC). The known risk factors for melanoma include sun exposure, pigmentation and nevus phenotypes; risk factors associated with RCC include smoking, obesity and hypertension. A recent study of coexisting melanoma and RCC in the same patients supports a genetic predisposition underlying the association between these two cancers. The microphthalmia-associated transcription factor (MITF) has been proposed to act as a melanoma oncogene; it also stimulates the transcription of hypoxia inducible factor (HIF1A), the pathway of which is targeted by kidney canc…

multidisciplinary sciencesMESH : Germ-Line MutationSUMO proteinurologic and male genital diseasesmedicine.disease_causeMESH : Neoplasm Invasiveness[ SDV.CAN ] Life Sciences [q-bio]/CancerMESH : Carcinoma Renal Cell0302 clinical medicineGene FrequencyCell MovementMESH: Germ-Line MutationMESH : Cell MovementMESH : Gene FrequencyMESH: Cell MovementComputingMilieux_MISCELLANEOUSGenetics0303 health sciencesMultidisciplinaryMESH: SumoylationMelanomaMESH : SumoylationMESH: Genetic Predisposition to Diseaserenal carcinomaMESH: Carcinoma Renal CellMicrophthalmia-associated transcription factorMESH : Microphthalmia-Associated Transcription Factor3. Good healthgermline mutation030220 oncology & carcinogenesisMESH: Microphthalmia-Associated Transcription Factorscience and technologyMESH: MelanomasumoMESH : Melanoma[SDV.CAN]Life Sciences [q-bio]/CancerBiology03 medical and health sciencesGermline mutationmelanomaMESH: Gene FrequencyGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseNeoplasm InvasivenessCarcinoma Renal CellneoplasmsTranscription factorGerm-Line Mutation030304 developmental biologyMicrophthalmia-Associated Transcription FactorMESH: HumansMESH : HumansSumoylationMESH: Neoplasm Invasivenessmedicine.diseaseHIF1Acancer cellsCancer researchMESH : Genetic Predisposition to DiseaseCarcinogenesis
researchProduct

The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: Implications in rheumatoid…

2009

Objective. Complement activation products contribute to a large number of inflammatory diseases, including RA. We have investigated whether osteoprotegerin (OPG) may concur with the soluble terminal complement complex (SC5b-9) to the inflammatory cascade characterizing RA. Methods. Levels of SC5b-9 and OPG in the plasma and SF of patients with active RA were determined by ELISA. The presence of SC5b-9 and OPG in RA synovial lesions was analysed by immunohistochemistry. Cultured endothelial cells were used for in vitro leucocyte/endothelial cell adhesion assays. In addition, endothelial cells were exposed to SC5b-9 in order to evaluate the effects on the production of OPG protein, as well as…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyComplement systemEndotheliumNeutrophilsArthritisInflammationComplement Membrane Attack ComplexArthritis RheumatoidEndothelium; Osteoprotegerin; Inflammation; Complement systemRheumatologyOsteoprotegerinInternal medicineCell AdhesionMedicineHumansPharmacology (medical)EndotheliumCells CulturedAgedInflammationEndothelial CellDose-Response Relationship Drugbusiness.industryNeutrophilSynovial MembraneOsteoprotegerinEndothelial CellsMiddle Agedmedicine.diseaseIn vitroComplement systemUp-RegulationEndothelial stem cellEndocrinologymedicine.anatomical_structureNeutrophil InfiltrationFemaleComplement system; Endothelium; Inflammation; Osteoprotegerin; Adult; Aged; Arthritis Rheumatoid; Cell Adhesion; Cells Cultured; Complement Membrane Attack Complex; Dose-Response Relationship Drug; Endothelial Cells; Endothelium Vascular; Female; Humans; Male; Middle Aged; Neutrophil Infiltration; Neutrophils; Osteoprotegerin; Synovial Membrane; Up-Regulation; Rheumatology; Pharmacology (medical)Endothelium Vascularmedicine.symptombusinessComplement membrane attack complexHuman
researchProduct

A ten-year follow-up of the Reflection cementless acetabular component.

2008

We reviewed the long-term results at ten to 12 years of 118 total hip replacements in 109 patients using a second-generation hemispherical cementless acetabular component (Reflection) designed to address the problem of backside wear. Five patients (five hips) died and six patients (seven hips) were lost to follow-up. The remaining 98 patients (106 hips) had a mean age of 62.9 years (34.0 to 86.2) A rate of revision for aseptic loosening of 0.9%, and predictable results were found with respect to radiological evidence of fixation, lack of pain, walking ability, range of movement and function. One component was revised for aseptic loosening, and of the 101 hips (95.2%) that did not have a rev…

musculoskeletal diseasesAdultmedicine.medical_specialtyAcetabulum; Adult; Aged; Aged 80 and over; Arthroplasty Replacement Hip; Bone Cements; Equipment Failure Analysis; Follow-Up Studies; Hip Joint; Humans; Middle Aged; Osteoarthritis Hip; Prosthesis Design; Prosthesis Failure; Statistics as Topic; Time Factors; Hip ProsthesisTime FactorsArthroplasty Replacement HipStatistics as TopicProsthesis DesignOsteoarthritis HipmedicineHumansOrthopedics and Sports MedicineSurvival analysisPelvisFixation (histology)AgedAged 80 and overbusiness.industryBone CementsAcetabulumMiddle AgedConfidence intervalSurgeryProsthesis FailureEquipment Failure AnalysisReflection acetabular component hipmedicine.anatomical_structureAcetabular componentRadiological weaponCohortOrthopedic surgerySurgeryHip JointHip ProsthesisbusinessFollow-Up StudiesThe Journal of bone and joint surgery. British volume
researchProduct

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

2020

Introduction We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). Methods ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. Results Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. Discussion Once AIH has been ruled out, the long-term outcomes and survival are un…

musculoskeletal diseasesMalemedicine.medical_specialtyAntibodies Antinuclear; Biopsy; England; Female; Humans; Italy; Longitudinal Studies; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prospective Studies; Survival AnalysisAnti-nuclear antibodyBiopsySettore MED/12 - GASTROENTEROLOGIAAntibodies Antinuclear Biopsy EnglandFemale Humans Italy Longitudinal Studies Male Middle Aged Non-alcoholic Fatty Liver Disease Prevalence Prospective StudiesSurvival AnalysisAutoimmune hepatitisMalignancyGastroenterologyAntibodies03 medical and health sciences0302 clinical medicineimmune system diseasesNon-alcoholic Fatty Liver DiseaseInternal medicineAntinuclearBiopsyNonalcoholic fatty liver diseasemedicineCarcinomaPrevalenceHumansLongitudinal StudiesProspective Studiesskin and connective tissue diseasesProspective cohort studySurvival analysisHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseases3. Good healthstomatognathic diseasesn/aEnglandItaly030220 oncology & carcinogenesisAntibodies Antinuclear030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct

Optimal positioning of the humeral component in the reverse shoulder prosthesis.

2014

Total reverse shoulder arthroplasty is becoming more and more the standard therapeutic practice for glenohumeral arthropathy with massive lesions of the rotator cuff. The biomechanical principle of this prosthesis is represented by the reversion of the normal anatomy of the shoulder joint. This non-anatomical prosthesis leads to a medialization of the rotation centre of the glenohumeral joint and also to a distalization of the humeral head. All that causes a deltoid tension increasing so allowing a larger abduction of the arm. Main complications of the reverse shoulder prosthesis are due to the joint instability, the scapular notching and the wear of the polyethylene insert. The main goal o…

musculoskeletal diseasesmedicine.medical_specialtyFEM analysesmedicine.medical_treatmentReplacementDeltoid curveProsthesis DesignProsthesisArthroplastyArthropathymedicineHumansOrthopedics and Sports MedicineHumerusRotator cuffArthroplasty ReplacementSettore ING-IND/15 - Disegno E Metodi Dell'Ingegneria IndustrialeTotal reverse shoulder arthroplasty Intrinsic stability FEM analyses Polyethylene wear Stability ratioFEM analyses; Intrinsic stability; Polyethylene wear; Stability ratio; Total reverse shoulder arthroplasty; Arthroplasty Replacement; Humans; Humerus; Prosthesis Design; Shoulder Joint; Orthopedics and Sports Medicine; Surgery; Medicine (all)business.industryShoulder JointMedicine (all)Intrinsic stabilityHumerusShoulder Prosthesismedicine.diseaseArthroplastySurgerymedicine.anatomical_structurePolyethylene wearStability ratioTotal reverse shoulder arthroplastySurgeryShoulder jointbusinesshuman activitiesMusculoskeletal surgery
researchProduct

A Navigation and Augmented Reality System for Visually Impaired People

2021

In recent years, we have assisted with an impressive advance in augmented reality systems and computer vision algorithms, based on image processing and artificial intelligence. Thanks to these technologies, mainstream smartphones are able to estimate their own motion in 3D space with high accuracy. In this paper, we exploit such technologies to support the autonomous mobility of people with visual disabilities, identifying pre-defined virtual paths and providing context information, reducing the distance between the digital and real worlds. In particular, we present ARIANNA+, an extension of ARIANNA, a system explicitly designed for visually impaired people for indoor and outdoor localizati…

navigation; visually impaired; computer vision; augmented reality; cultural context; convolutional neural network; machine learning; hapticExploitComputer scienceconvolutional neural networkImage processingContext (language use)02 engineering and technologyTP1-1185BiochemistryConvolutional neural networkArticleMotion (physics)computer visionAnalytical ChemistrySettore ING-INF/04 - AutomaticaArtificial IntelligenceHuman–computer interactioncultural context0202 electrical engineering electronic engineering information engineeringHumansElectrical and Electronic EngineeringnavigationInstrumentationHaptic technologySettore ING-INF/03 - TelecomunicazioniChemical technology020206 networking & telecommunicationsAtomic and Molecular Physics and Opticsaugmented realitymachine learning020201 artificial intelligence & image processingAugmented realityvisually impairedNeural Networks ComputerhapticAlgorithmsVisually Impaired PersonsPATH (variable)augmented reality computer vision convolutional neural network cultural context haptic machine learning navigation visually impaired Algorithms Artificial Intelligence Humans Neural Networks Computer Augmented Reality Visually Impaired PersonsSensors
researchProduct

Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…

2021

Most anticancer molecules are administered in body-size-based dosing schedules, bringing up unsolved issues regarding pharmacokinetic data in heavy patients. The worldwide spread of obesity has not been matched by improved methods and strategies for tailored drug dosage in this population. The weight or body surface area (BSA)-based approaches may fail to fully reflect the complexity of the anthropometric features besides obesity in cancer patients suffering from sarcopenia. Likewise, there is a lack of pharmacokinetic data on obese patients for the majority of chemotherapeutic agents as well as for new target drugs and immunotherapy. Therefore, although the available findings point to the …

obesityCancer Researchmedicine.medical_specialtypharmacokinetic parametersConsensusBSAcancer drug dosingPopulationchemotherapy doseAntineoplastic AgentsReviewOverweightNODosing schedulesNeoplasmsPhysiciansInternal medicineHumansMedicineDosingLS4_3educationBody surface areaeducation.field_of_studybusiness.industryCancerCytotoxic chemotherapymedicine.diseaseOncologyBSA; cancer drug dosing; chemotherapy dose; obesity; pharmacokinetic parametersPosition paperBSA; cancer drug dosing; chemotherapy dose; obesity; pharmacokinetic parameters; Consensus; Humans; Obesity; Antineoplastic Agents; Neoplasms; Physiciansmedicine.symptombusinessESMO Open
researchProduct